Su­cam­po shut­ters de­vel­op­ment ef­fort af­ter lead drug flops in back-to-back stud­ies

Back in April, when Su­cam­po’s lead ex­per­i­men­tal drug co­bipro­s­tone flunked its first mid-stage study, the Rockville, MD-based biotech stub­born­ly in­sist­ed that an on­go­ing study for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER